

ASX RELEASE

20 NOVEMBER 2018

APPOINTMENT OF ABBAS HUSSAIN TO THE COCHLEAR LIMITED BOARD

Cochlear Limited, Sydney, 20 November 2018 (ASX: COH) today announced the appointment of Abbas Hussain to the Cochlear Board. Mr Hussain's appointment will become effective on 1st December 2018.

Mr Hussain has worked in the pharmaceutical industry for 30 years and has significant global experience in building relationships with professionals within the healthcare industry.

Mr Hussain's most recent executive role was Global President, Pharmaceuticals at GlaxoSmithKline (GSK) where he had overall responsibility for the Company's business and led operations supporting commercial infrastructure, including medical, finance, human resources, IT, legal and communications. Mr Hussain managed GSK's global pharmaceuticals and vaccine business across 150 markets including the US, Europe, Japan and emerging markets. He also has experience in the areas of research & development, quality control and capital investments.

Cochlear Chairman, Mr Rick Holliday-Smith welcomed Mr Hussain's appointment: "Given his knowledge in pharmaceuticals, Abbas will bring experience and expertise to prioritisation of business development and growth opportunities across unique and diverse markets. Abbas is well-equipped to provide valuable strategic insight and has demonstrated strong values in customer focus which is intrinsic to Cochlear's strategic platforms. His career has been spent at the forefront of emerging markets and his deep experience in China and India will be invaluable as these represent key emerging markets for Cochlear."

Mr Hussain is currently a Non-Executive Director of CSL Limited and Immunocore Limited. He is also a senior advisor to CellResearch Corp and C-Bridge Capital.

Mr Hussain holds a BSc Honours degree in Medicinal Chemistry and Pharmacology and a Graduate Diploma of Industrial Studies from Loughborough Institute of Technology, 1988.

Mr Hussain will be a Non-Executive Director and is considered by the Board to be independent. He resides in the United Kingdom.

For further information, please contact:

Analysts

Kristina Devon
Head of Investor Relations
Email: kdevon@cochlear.com
Ph: + 61 2 9611 6691

Media

Jennifer Stevenson
Head of Corporate Communications
Email: jstevenson@cochlear.com
Ph: +61 2 9611 6959